Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01389024 · ClinicalTrials.gov registry record · Phase 2
Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01389024: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT01389024 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01389024, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a pilot study of hydroxyurea versus placebo to reduce central nervous system complications (abnormally fast blood flow to the brain, silent cerebral infarct or stroke) in young children with sickle cell disease. The investigators plan to identify children 12 to 48 months old without central nervous system complications and randomly assign 20 to treatment with hydroxyurea and 20 to treatment with placebo for 36 months. Neither the study doctors nor the participants will know which treatment they are receiving.
Interventions
- DRUG Placebo
- DRUG Hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-08-16 |
| Est. Completion | 2022-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01389024
The ClinicalTrials.gov registry entry for NCT01389024 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01389024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01389024 about?
NCT01389024 is a clinical study titled "Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease". This is a pilot study of hydroxyurea versus placebo to reduce central nervous system complications (abnormally fast blood flow to the brain, silent cerebral infarct or stroke) in young children with sickle cell disease. The investigators plan to identify children 12 to 48 months old without central ...
What is the current status of trial NCT01389024?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2012-08-16. Estimated completion is 2022-05-24.
What interventions are being tested in trial NCT01389024?
The interventions under investigation include: Placebo (DRUG), Hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT01389024?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.